百洋医药（301015）公告，2025年一季度实现营业收入18.41亿元，同比下降0.38%；净利润8501.28万 元，同比下降54.36%。 ...

近期鹭燕医药（002788）发布2025年一季报，证券之星财报模型分析如下： 财务概况 近期鹭燕医药发布了2025年一季报。报告显示，鹭燕医药在该季度实现了营业总收入51.74亿元，同比 上升0.74%，但归母净利润为7132.36万元，同比下降14.86%。扣非净利润为7088.61万元，同比下降 14.33%。 商业模式与财务健康度 鹭燕医药的业绩主要依靠营销驱动，需要仔细研究这类驱动力背后的实际情况。根据财报体检工具的建 议，需特别关注以下几点： 综上所述，鹭燕医药在2025年一季度虽然实现了营业收入的小幅增长，但净利润却出现了较大幅度的下 滑，且公司在现金流和债务方面存在一定的风险，需持续关注其后续的经营情况和财务健康度。 毛利率：7.0%，同比减少4.97% 净利率：1.35%，同比减少17.11% 三费占营收比：4.72%，同比减少1.28% 每股净资产：8.32元，同比增长7.24% 每股经营性现金流：-0.21元，同比增长23.37% 每股收益：0.18元，同比减少18.18% 现金流状况：货币资金/流动负债仅为7.3%，近3年经营性现金流均值/流动负债仅为11.27%，表明 公司现金流状况较 ...

从指数持仓来看，中证全指医疗行业指数十大权重分别为：迈瑞医疗（14.15%）、爱尔眼科 （8.89%）、联影医疗（7.82%）、爱美客（4.05%）、惠泰医疗（4.0%）、鱼跃医疗（3.12%）、上海 医药（3.09%）、新产业（3.03%）、益丰药房（2.65%）、美年健康（2.5%）。 金融界4月22日消息，A股三大指数收盘涨跌不一，中证全指医疗行业指数 (医疗行业，932131)报537.08 点。 数据统计显示，中证全指医疗行业指数近一个月下跌5.24%，近三个月下跌0.28%，年至今下跌5.24%。 据了解，中证全指行业优选指数系列从中证全指行业中选取符合一定流动性与市值筛选条件的上市公司 作为指数样本，以反映各个行业内较具代表性与可投资性的上市公司证券的整体表现。该指数以2021年 12月31日为基日，以1000.0点为基点。 资料显示，指数样本每半年调整一次，样本调整实施时间分别为每年6月和12月的第二个星期五的下一 交易日。权重因子随样本定期调整而调整，调整时间与指数样本定期调整实施时间相同。在下一个定期 调整日前，权重因子一般固定不变。遇临时调整时，当中证全指指数调整样本时，中证全指行业指数 ...

Core Viewpoint - Chongqing Pharmaceutical Holdings (重药控股) faces regulatory scrutiny due to inaccuracies in its 2023 financial reporting, leading to a decline in stock price and concerns over potential earnings manipulation [2][3]. Financial Performance - In 2023, Chongqing Pharmaceutical Holdings reported revenue of approximately 801.2 billion yuan, an increase of 18.12% year-on-year, while net profit decreased by 31.22% to about 6.55 billion yuan [3]. - The company's cash flow from operating activities showed a significant increase of 77.92%, reaching approximately 5.09 billion yuan [3]. - The company anticipates a decline in net profit for 2024, projected between 290 million and 390 million yuan, representing a year-on-year decrease of 40.45% to 55.72% [3]. Business Operations - The company primarily engages in pharmaceutical commerce, logistics, and industrial research, with a core focus on pure sales business, supplying pharmaceuticals and medical devices directly to hospitals and medical institutions [2]. - Chongqing Pharmaceutical Holdings has over 7,800 secondary and above pure sales customers, with pure sales accounting for approximately 79.37% of total sales, amounting to 635.94 billion yuan [3]. Regulatory Actions - The Chongqing Securities Regulatory Bureau issued an administrative regulatory measure against the company, citing issues such as improper revenue recognition and lack of commercial substance in certain transactions [2]. - The company's chairman, general manager, and financial director have been subjected to regulatory discussions as part of the measures taken [2]. Ownership Changes - In January 2023, the actual controller of Chongqing Pharmaceutical Holdings changed from the Chongqing State-owned Assets Supervision and Administration Commission to the State-owned Assets Supervision and Administration Commission of the State Council [4]. - The change in control was due to the transfer of 2% equity from Chongqing Chemical Medicine to China General Technology Group [5].

4月21日，塞力医疗今日收盘9.87元，上涨2.39%，最新市净率1.93，总市值18.85亿元。 最新一期业绩显示，2024年三季报，公司实现营业收入14.20亿元，同比-7.15%；净利润-56025062.27 元，同比-1368.70%，销售毛利率19.89%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)2塞力医疗-8.94-11.891.9318.85亿行业平均 23.6322.711.80104.91亿行业中值18.9916.091.3056.98亿1漱玉平民-103.9232.812.1043.66亿3海王生 物-3.46-3.551.9859.99亿4柳药集团7.847.840.9067.01亿5鹭燕医药8.548.870.9530.65亿6国药股份 11.1111.111.30222.13亿7英特集团11.2911.041.2353.96亿8南京医药11.3611.360.9564.81亿9九州通 11.7311.040.97240.02亿10健之佳13.127.501.1231.06亿11百洋医药13.6715.654.65102.71亿 来源：金融界 股东方面，截至2024年 ...

Financial Performance - The company's basic earnings per share for Q1 2025 is 0.1800 yuan, a decrease of 18.18% compared to Q1 2024, which was 0.2200 yuan [1] - The net profit for Q1 2025 is 0.71 billion yuan, down 15.48% from 0.84 billion yuan in Q1 2024 [1] - The return on equity (ROE) for Q1 2025 is 2.23%, a decline of 20.36% from 2.80% in Q1 2024 [1] - The total revenue for Q1 2025 is 51.74 billion yuan, showing a slight increase of 0.74% from 51.36 billion yuan in Q1 2024 [1] Shareholder Structure - The top ten unrestricted shareholders hold a total of 15,797.43 million shares, accounting for 41.39% of the circulating shares, with a decrease of 126.77 million shares compared to the previous period [2] - Xiamen Maidi Ken Technology Co., Ltd. remains the largest shareholder with 13,803.07 million shares, representing 36.17% of the total share capital [2] - New entrants in the top ten shareholders include China Merchants Fund Management Co., Ltd. - Social Security Fund 1903 Portfolio and Chen Feng, holding 165.77 million shares (0.43%) and 145.00 million shares (0.38%) respectively [2] Dividend Policy - The company has announced that it will not distribute dividends or transfer shares this time [3]

一、主要会计数据和财务指标 三、分红送配方案情况 本次公司不分配不转赠。 二、前10名无限售条件股东持股情况 前十大流通股东累计持有： 5131.81万股，累计占流通股比： 37.22%，较上期变化： 2177.57万股。 | 名称 持有数量(万股) | | 占总股本比例 | 增减情况(万 | | --- | --- | --- | --- | | | | (%) | 股) | | 王毅清 | 1753.61 | 12.72 | 新进 | | 长沙同嘉投资管理合伙企业(有限合伙) | 980.00 | 7.11 | 新进 | | 桐乡稼沃云枫股权投资合伙企业(有限合伙) | 571.43 | 4.14 | 不变 | | 宁波梅山保税港区量吉股权投资合伙企业(有限合 | | | | | 伙) | 546.62 | 3.96 | -89.91 | | 钟雪松 | 482.21 | 3.50 | 不变 | | 宁波梅山保税港区淳康股权投资合伙企业(有限合 伙) | 301.99 | 2.19 | -41.00 | | 刘建强 | 179.65 | 1.30 | -111.08 | | 明晖 | 140.00 | 1 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：600829 证券简称：人民同泰 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存在虚假 记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人朱卫东、主管会计工作负责人管平及会计机构负责人（会计主管人员）张鉴保证季度报告中 财务信息的真实、准确、完整。 第一季度财务报表是否经审计 □是 √否 一、主要财务数据 (一)主要会计数据和财务指标 单位：元 币种：人民币 ■ 报告期内，公司营业收入266,681.01万元，同比增加6,877.48万元，增长2.65%，主要原因：一是批发商 业业务，公司深入挖掘潜力客户资源，商业销售同比增长；二是零售业务，公司推进DTP业务销售发 展，通过积极承接处方外流市场，丰富DTP经营品种，持续提升员工专业药事服务能力，零售板块销售 同比增长；三是器械业务销售同比增长。 报告期内，公司归属于上市公司股东的净利润4,584.09 ...

Group 1 - The event on April 18 was co-hosted by the People's Bank of China Jiangsu Branch, Jiangsu Securities Regulatory Bureau, and Nanjing Municipal Government, focusing on the stock repurchase and increase re-loan policy [1] - Over 200 guests from regulatory bodies, state-owned assets supervision, local government, 26 financial institutions, 120 listed companies, and mainstream media participated in discussions about the stable operation of the capital market and effective policy implementation [1][3] - The People's Bank of China introduced a special re-loan policy for stock repurchase and increase in September 2024, aimed at providing targeted financial support to help listed companies stabilize market expectations, optimize equity structure, and enhance risk resistance [3] Group 2 - China Bank Jiangsu Branch has established a special working group to proactively address corporate demands, focusing on stock repurchase, cross-border financing, and mergers and acquisitions [3] - As of now, the bank has approved special quotas for 28 listed companies totaling nearly 10 billion yuan, covering key industries such as manufacturing, information technology, and biomedicine, with the approval amount and number ranking among the top in the market [3] - The bank aims to strengthen collaboration with government, regulators, listed companies, and media to enhance policy implementation and support the stability and growth of enterprises [4]

重药控股收到深交所监管函，公司存在以下问题：2023年，部分收入未实质取得货物控制权，错误适用 总额法进行确认；部分收入在期后大额退货，且无有效证明材料、无合理退货理由；部分收入无商业实 质；部分收入实际确认时点与公司已披露会计政策不符，上述问题导致公司2023年年度报告财务信息披 露不准确。公司的上述行为违反了相关规定。公司董事长袁泉、总经理刘伟、财务总监兼董秘邱天未履 行勤勉尽责义务，违反了相关规定，对上述问题负有主要责任。 ...